Navigation Links
Phase III Study Evaluating Gilead's Viread for the Treatment of,Chronic Hepatitis B Virus Meets Primary Endpoint

"We believe Viread has the potential to be an important treatment option for patients with chronic hepatitis B and look forward to sharing detailed data from this study at a scientific conference later this year."

Study 102 is one of two Phase III pivotal studies evaluating the efficacy, safety and tolerability of Viread for the treatment of chronic hepatitis B. The second study (Study 103), a 48-week trial among patients with hepatitis B "e" antigen (HBeAg)-positive chronic hepatitis B, is expected to be complete later this year.

The active ingredient in Viread, tenofovir DF, is currently the most prescribed molecule in the United States for combination HIV therapy. Viread received approval as an anti-HIV medication from the U.S. Food and Drug Administration (FDA) in October 2001 and from the European Commission in February 2002. Viread is not approved as a treatment for chronic hepatitis B, and data from this analysis have not been reviewed by the FDA.

Study Design

Study 102 is a multi-center, randomized, double-blind Phase III clinical trial that compares the efficacy, safety and tolerability of Viread and Hepsera over 48-weeks among patients with HBeAg-negative/anti-HBe positive (presumed pre-core mutant) chronic hepatitis B. Three hundred and seventy-five patients were randomized in a 2:1 ratio to receive either tenofovir DF (300 mg once daily; n=250) or Hepsera (10 mg once daily; n=125).

About Viread (tenofovir disoproxil fumarate)

In the United States, Viread is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. Viread should not be used in combination with the fixed-dose combination products Truvada(R) or Atripla(TM) because they already contain Viread.

Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues alone or in combination with other antiretrovirals. Viread is not approved for t
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
2. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
3. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
7. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
8. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
9. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
10. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
11. Phase III Trial Results Show Superiority of Rivaroxaban over Enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Knee Replacement Surgery
Post Your Comments:
(Date:3/27/2015)... -- Holographic Optical Technologies of Augusta, Georgia ... is entering the world of consumer electronics with the ... th , 2015, the campaign will introduce the company,s ... displays will allow consumers to view fully three dimensional ... to the two displays, the company will also offer ...
(Date:3/27/2015)... YORK , March 27, 2015 A new ... Latin America – Chile ... are top targets for IVD firms.  The healthcare ... figures heavily into IVD strategies for the Latin American continent ... to support globally distributed supply operations. However, the country,s regional ...
(Date:3/27/2015)... Report Details  New study shows ... What does the future hold for top companies ... new report shows you potential revenues to 2025, assessing ... 242-page report provides 185 tables, charts, and graphs. Discover ... future market prospects. Our new study lets you assess ...
Breaking Medicine Technology:Holographic Optical Technologies brings cutting-edge holograms to consumer market through upcoming Kickstarter campaign 2Holographic Optical Technologies brings cutting-edge holograms to consumer market through upcoming Kickstarter campaign 3Kalorama: Beyond Brazil, Latin American IVD Market Grows 2Kalorama: Beyond Brazil, Latin American IVD Market Grows 3Kalorama: Beyond Brazil, Latin American IVD Market Grows 4Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 2Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 3Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 4Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 5Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 6Pharma Leader Series: Top 25 Ophthalmic Drug Manufacturers 2015-2025 7
(Date:3/28/2015)... 28, 2015 Pitching speed, player’s height, and ... shoulder and elbow injuries, according to new research released today ... ) Specialty Day. , “Our findings indicate that a 10 ... in likelihood of a history of injury, a 10 mile ... increase likelihood of a history of injury, and playing for ...
(Date:3/28/2015)... NV (PRWEB) March 28, 2015 Early ... patients with Type V AC joint injuries, according to ... presented today at the American Orthopaedic Society for Sports ... returned to duty faster when surgery was not performed. ... with 7 receiving surgical treatment and 17 receiving non-surgical ...
(Date:3/28/2015)... March 28, 2015 Aureus Medical ... staffing, including physical therapy jobs, has announced that ... Ohio Physical Therapy Association Annual Conference to be ... Downtown Hotel in Columbus, OH. , The ... and exhibits with products and services. , ...
(Date:3/28/2015)... ARDX will sponsor the 7th Annual Women’s Wellness ... Chesapeake Conference Center in Chesapeake, Virginia. Each year, ARDX ... women in the Hampton Roads region. The 2015 Women’s ... Women grow stronger through sharing their stories and learning ... the WWC™ theme is T-talk where we will share a ...
(Date:3/27/2015)... 27, 2015 The Monogamy Method ... experts Samantha Sanderson and Jason Rogers has just been ... media attention. The commotion surrounding the course's launch has ... to publish an in-depth review of the new program. ... men in their lives suddenly start pulling away or ...
Breaking Medicine News(10 mins):Health News:Researchers Highlight Shoulder and Elbow Injury Possibility in Youth Players 2Health News:For Type V AC Joint Injuries, Early Surgery May Not Be the Best Approach 2Health News:Healthcare Staffing Leader, Aureus Medical Group, to Exhibit at the Ohio Physical Therapy Association Annual Conference 2Health News:The Monogamy Method - Review Of Samantha Sanderson & Jason Rogers' Relationship Program Released 2
... study finds that people who receive higher disability ratings ... the long term than those who get lower ratings.// ... first to examine the relationship between Workers’ Compensation settlements ... which reinforces previous research showing ‘blacks receive less treatment ...
... suggests that patients who receive transfusions during heart bypass ... infections, and dying, after their operation. ,In ... medical mystery: why women bypass patients are more likely ... after surgery. Women are more likely to receive blood ...
... Kidney stones in children—considered all but a medical aberration ... a growing and disturbing trend that has pediatricians at ... sounding the alarm. ,While doctors have yet to ... behind it—better detection devices probably play some role—pediatricians agree ...
... strategy to combat malaria is abuzz, and the main action ... // ,The researchers from the National Institutes of Health ... mice, instigated them to produce antibodies against the parasite, Plasmodium ... of the mice, gain access into the mosquito’s body, through ...
... expressed their shock and disappointment on hearing the news ... //sentences on five Bulgarian nurses and one Palestinian doctor ... ,George Bush has expressed his "disappointment" to ... Bulgaria's attempts to strive for the release of the ...
... Muir Beach, CA, was living day-to-day, extremely ill, with ... dependent// on kidney dialysis. She needed a kidney transplant ... her doctors believed that a transplant was not possible ... specialized type of anti-rejection therapy pioneered at Cedars-Sinai Medical ...
Cached Medicine News:Health News:Is Workers’ Comp. Settlements for Back Pain Fair 2Health News:Blood Transfusions Raise Heart Patients’ Infection and Death Ris 2Health News:Blood Transfusions Raise Heart Patients’ Infection and Death Ris 3Health News:Kidney Stones Occurring More Often in Children 2Health News:Anti-rejection Therapy a Boon for Patients With "anti-donor" Antibody Levels 2Health News:Anti-rejection Therapy a Boon for Patients With "anti-donor" Antibody Levels 3Health News:Anti-rejection Therapy a Boon for Patients With "anti-donor" Antibody Levels 4
Irrigating Capsulorhexis Cystotome. Formed blunt tip, 25 g. Overall length 22 mm. 5/box....
Irrigating Cystotome, formed, 23 g., 12 mm curved tip. Overall length 14 mm. 5/box....
Retrobulbar Needle, 25 g. Atkinson style bevel. Overall length 38 mm. 5/box....
Peribulbar Needle, 23 g. Atkinson style bevel. Overall length 31 mm. 5/box....
Medicine Products: